close
MENU
Investment
3 mins to read

Pacific Edge warns risk of non-coverage ‘more elevated’

Second quarter update shows testing volumes fell following a sales restructure and publicity around Medicare’s coverage determination.

Pacific Edge makes the Cxbladder product, a non-invasive urine test for bladder cancer.

Dual-listed cancer diagnostics company Pacific Edge has warned the risk of a non-coverage decision from Medicare for its Cxbladder product is now “more elevated than we assessed for much of the last year”.

Meanwhile, test volumes in the second quarter of the 2024 financial year have fallen 12%,

Want to read more? It's easy.

Choose your best value subscription option

Student

Exclusive offer for uni students studying at a New Zealand university (valued at $499).
Individual
Group membership
NBR Marketplace
NZ Aviation News

Yearly Premium Online Subscription

NZ$499.00 / yearly

Monthly Premium Online Subscription

NZ$44.95 / monthly

Smartphone Only Subscription

NZ$24.95 / monthly

Premium Group Membership 10 Users

NZ$350+GST / monthly

$35 per user - Pay by monthly credit card debit

Premium Group Membership 20 Users

NZ$600+GST / monthly

$30 per user - Pay by monthly credit card debit

Premium Group Membership 50 Users

NZ$1250+GST / monthly

$25 per user - Pay by monthly credit card debit

Premium Group Membership 100 Users

NZ$1875+GST / monthly

$18.75 per user - Pay by monthly credit card debit

Yearly Premium Online Subscription + NBR Marketplace

NZ$499.00 / yearly

Aviation News - Monthly

NZ$14.95 / monthly

Already have an account? Login
Contact the Writer: Hmcnicol@nbr.co.nz
News tip? Question? Typo? Let us know: editor@nbr.co.nz
© All content copyright NBR. Do not reproduce in any form without permission, even if you have a paid subscription.
Company profile
Powered by: nzx logo
Change:
Price
Previous Close
Turnover
Movement
Volume
Avg Daily Volume
Daily High
Daily Low
52 Week High
52 Week Low
Pacific Edge warns risk of non-coverage ‘more elevated’
Investment,
101199